<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861471</url>
  </required_header>
  <id_info>
    <org_study_id>NYU 04-47 (H12554)</org_study_id>
    <secondary_id>Novartis CSTI571BUS200</secondary_id>
    <nct_id>NCT00861471</nct_id>
  </id_info>
  <brief_title>Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer</brief_title>
  <official_title>Phase I/II, Open Label Study of Sequential Taxotere® (Docetaxel) and Gleevec® (Imatinib Mesylate) in Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to determine the proper doses of Docetaxel and Imatinib mesylate to be&#xD;
      used to treat hormone refractory prostate cancer and to evaluate the safety and efficacy of&#xD;
      the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen-independent prostate cancer is the second most common cause of cancer death in men.&#xD;
      These patients have limited treatment options. Docetaxel(Taxotere) is the single most active&#xD;
      agent for the treatment of hormone refractory prostate cancer. Phase II clinical trials&#xD;
      including docetaxel combinations with other microtubule inhibitors have shown 60-70% prostate&#xD;
      specific antigen (PSA) declines greater than 50% and 30-40% measurable disease responses.&#xD;
      However, the duration of response is limited to roughly 22 weeks. Combinations with new&#xD;
      agents are needed to increase the rate and duration of response over existing docetaxel&#xD;
      containing combinations.&#xD;
&#xD;
      The platelet derived growth factor receptor(PDGFR)and platelet derived growth factor (PDGF) A&#xD;
      are frequently expressed (80%) in primary and bone marrow metastasis of human prostate cancer&#xD;
      (PC). Recent experimental evidence suggests that activation of PDGFR/PDGF can be oncogenic in&#xD;
      the development and/or progression of PC. There is also evidence that PC cells that express&#xD;
      PDGF promote PDGFR expression in endothelial cells and neo- angiogenesis. Together, these&#xD;
      experimental evidence supports that inhibition of PDGFR may be of therapeutic benefit to&#xD;
      advanced prostate cancer patients.&#xD;
&#xD;
      Gleevec (Imatinib mesylate ) is a potent inhibitor of PDGFR. Consistent with these&#xD;
      observations, treatment with Gleevec in an experimental prostate cancer mouse model was&#xD;
      better than paclitaxel alone in reducing bone metastasis but the antitumor effect was&#xD;
      strongest with the combination of both. In a phase I study of heavily pretreated hormone&#xD;
      refractory PC patients, Gleevec 600 mg/daily lead-in for 30 days followed by Gleevec 600&#xD;
      mg/daily with Paclitaxel 30mg/m2 weekly x4 weeks every 6 weeks induced a &gt;50% PSA decline in&#xD;
      7% and 38% of patients respectively with acceptable toxicity. These observations suggested&#xD;
      that this combination merits further investigation.&#xD;
&#xD;
      With high-dose docetaxel (70mg/m^2) being the single most active agent in hormone refractory&#xD;
      prostate cancer and no data existing in the use of high-docetaxel with Gleevec, a phase I/II&#xD;
      study to determine the maximum tolerated dose (MTD) of the combination and optimum dose for a&#xD;
      phase II trial is warranted.&#xD;
&#xD;
      Gleevec is expected to affect the activation status of sensitive receptor tyrosine kinase&#xD;
      targets and associated signaling effectors in the tumor cells and the neovasculature.&#xD;
      However, it is not fully established to what extent alterations of the target and /or other&#xD;
      molecules in the signaling pathway are essential for Gleevec's antitumor activity in prostate&#xD;
      cancer patients. It is also unknown whether preexisting molecular changes in the prostate&#xD;
      tumors of individual patients could affect Gleevec's activity even in the presence of the&#xD;
      targets. Therefore, an assessment of the expression levels and/or presence of mutations of&#xD;
      selected molecules in specimens of patients in clinical trials may contribute in various&#xD;
      ways: 1. to understand the requirements to elicit or inhibit a response to the combination,&#xD;
      2. whether adding other targeted agents may improve response and/or 3. whether selection of&#xD;
      patients that might benefit should be based on the tumor profile. Thus, whenever possible&#xD;
      specimens form the primary and/or metastatic sites should be retrieved and/or obtained to&#xD;
      perform these analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to slow accrual&#xD;
  </why_stopped>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Prostate Specific Antigen (PSA) Response</measure>
    <time_frame>up to 9 months</time_frame>
    <description>PSA response is defined as a greater than or equal to a 50% decrease in PSA from the baseline without clinical or radiologic evidence of progression according to the Response Evaluation Criteria in Solid Tumors (RECIST). PSA concentration was measured at baseline on day 1/cycle 1 before treatment, then day 1 of every cycle afterwards during therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Greater or Equal to 80% PSA Reduction From Baseline Without Clinical or Radiologic Evidence of Progression</measure>
    <time_frame>up to 9 months</time_frame>
    <description>PSA was measured at baseline on day 1/cycle 1 before treatment, then day 1 of every cycle afterwards during therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Measurable Disease Response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Measurable disease response is defined as the number of participants whose best response is complete response or partial response over the number of patients with measurable desease according to the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time to PSA pregression is defined as the time at which therapy statred and ends when the PSA increased by 50% above the nadir confirmed on a second determination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival Time</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Overall survival time is the time from the start of therapy till death. Median overall survival reported here is the time when 50% of the participants are alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Docetaxel +Gleevec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>One treatment cycle is defined as 21 days.&#xD;
Docetaxel: 70 mg/m^2 (60 mg/m^2 was tested in Phase I as well), Intravenous, every 21 days.</description>
    <arm_group_label>Docetaxel +Gleevec</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>One treatment cycle is defined as 21 days.&#xD;
Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days.</description>
    <arm_group_label>Docetaxel +Gleevec</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at least 18 years of age.&#xD;
&#xD;
          -  Histologically documented diagnosis of adenocarcinoma of prostate gland&#xD;
&#xD;
          -  Patients must have hormone refractory prostate cancer having progressed after at least&#xD;
             two prior hormonal manipulations with documented castrate levels of testosterone (&lt;50&#xD;
             ng/dl). PSA ≥ 5 ng/ml&#xD;
&#xD;
          -  Patients must have hormone-refractory prostate carcinoma as evidenced by PSA&#xD;
             progression, with or without evidence of measurable disease, or evaluable disease by a&#xD;
             positive bone scan. PSA progression is defined as &gt; 25% increase in 2 consecutive&#xD;
             tests in which the first increase in PSA should occur a minimum of 1 week from the&#xD;
             reference value and this increase in PSA should be confirmed and ≥ 5 ng/ml&#xD;
&#xD;
          -  Eligible patients will have been treated with at least two prior hormonal&#xD;
             manipulations including androgen deprivation and may have received one prior&#xD;
             chemotherapy regimen.&#xD;
&#xD;
          -  Any chemotherapy, major surgery, or irradiation must have been completed at least 3&#xD;
             weeks prior to starting study drugs. Patient must have recovered from clinically&#xD;
             significant toxicities incurred as a result of previous therapy except nail dystrophy,&#xD;
             alopecia, grade 1 peripheral neuropathy, or radiation therapy induced affects (i.e.,&#xD;
             impotence or incontinence)&#xD;
&#xD;
          -  No recent prior flutamide (Eulexin) use within the past 4 weeks, prior bicalutamide&#xD;
             (Casodex) use within the past 6 weeks, or prior nilutamide (Nilandron) use within the&#xD;
             past 6 weeks.&#xD;
&#xD;
          -  Performance status 0,1, 2 (Eastern Cooperative Oncology Group performance status&#xD;
             scale)&#xD;
&#xD;
          -  Adequate end organ function, defined as the following:&#xD;
&#xD;
               -  total bilirubin &lt; 1.5 x upper limit of Normal (ULN)&#xD;
&#xD;
               -  Serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic pyruvic&#xD;
                  transaminase (SGPT) &lt; 2.5 x ULN&#xD;
&#xD;
               -  creatinine &lt; 1.5 x ULN&#xD;
&#xD;
               -  Absolute Neutrophil count (ANC) &gt; 1.5 x 10^9/L&#xD;
&#xD;
               -  platelets &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Written, voluntary informed consent.&#xD;
&#xD;
          -  Patients must have been and continue to be on androgen deprivation therapy with a&#xD;
             Luteinizing hormone-releasing hormone (LHRH) agonist or antagonist during study&#xD;
             participation except for patients who had orchiectomy.&#xD;
&#xD;
          -  Patients on secondary hormonal manipulation with ketoconazole and hydrocortisone who&#xD;
             discontinued LHRH therapy must be switched to single agent LHRH analogue therapy&#xD;
             unless they had orchiectomy.&#xD;
&#xD;
          -  Patients being treated with Zometa prior to the initiation of the study will be&#xD;
             permitted to continue with Zometa while on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has received any other investigational agents within 28 days of first day of&#xD;
             study drug dosing, unless the disease is rapidly progressing.&#xD;
&#xD;
          -  Patient is &lt; 5 years free of another primary malignancy except: if the other primary&#xD;
             malignancy is not currently clinically significant nor requiring active intervention,&#xD;
             or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in&#xD;
             situ. Existence of any other malignant disease is not allowed.&#xD;
&#xD;
          -  Patient with Grade III/IV cardiac problems as defined by the New York Heart&#xD;
             Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6&#xD;
             months of study)&#xD;
&#xD;
          -  Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,&#xD;
             chronic renal disease, or active uncontrolled infection).&#xD;
&#xD;
          -  Patient with untreated brain metastasis or cord compression. However, patients with&#xD;
             treated spinal cord compression or central nervous system (CNS) metastases that have&#xD;
             been stable are eligible.&#xD;
&#xD;
          -  Patient has known chronic liver disease (i.e., chronic active hepatitis, and&#xD;
             cirrhosis).&#xD;
&#xD;
          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C)&#xD;
             prior to study entry, unless the disease is rapidly progressing.&#xD;
&#xD;
          -  Patient previously received radiotherapy to at least 25 % of the bone marrow&#xD;
&#xD;
          -  Patient had a major surgery within 2 weeks prior to study entry.&#xD;
&#xD;
          -  Patient with any significant history of non-compliance to medical regimens or with&#xD;
             inability to grant reliable informed consent.&#xD;
&#xD;
          -  If the patient is taking steroids for prostate cancer, then the patient is ineligible&#xD;
             for this study. If the patient is taking steroids for conditions other than prostate&#xD;
             cancer, the patient is eligible provided that the reasons for use and dosage are&#xD;
             documented. The investigator is urged to discuss this issue with the Study Principal&#xD;
             Investigator for any clarification.&#xD;
&#xD;
          -  No therapeutic anticoagulation with warfarin (e.g. Coumadin® or Coumadine®) will be&#xD;
             permitted in patients participating in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Ferrari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Tisch Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <results_first_submitted>April 29, 2011</results_first_submitted>
  <results_first_submitted_qc>June 2, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2011</results_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormone refractory prostate cancer</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>Gleevec</keyword>
  <keyword>PSA</keyword>
  <keyword>prostate specific antigen</keyword>
  <keyword>growth factor receptor inhibitor</keyword>
  <keyword>androgen independent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 patients were enrolled between Sep. 2006 and Nov. 2008 for the Phase II part of the study in New York University Medical center and affiliated hospitals.</recruitment_details>
      <pre_assignment_details>Once the optimal combination dose of Docetaxel (Taxotere) and Gleevec (Imatinib Mesylate) was determined in the Phase I part, the study proceeded to Phase II. There were 12 patients in Phase I and Phase II, respectively. The results reported here are only for Phase II.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel +Gleevec</title>
          <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>treatment for lumbar laminectomy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel +Gleevec</title>
          <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Prostate Specific Antigen (PSA) Response</title>
        <description>PSA response is defined as a greater than or equal to a 50% decrease in PSA from the baseline without clinical or radiologic evidence of progression according to the Response Evaluation Criteria in Solid Tumors (RECIST). PSA concentration was measured at baseline on day 1/cycle 1 before treatment, then day 1 of every cycle afterwards during therapy.</description>
        <time_frame>up to 9 months</time_frame>
        <population>The analysis was based on intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel +Gleevec</title>
            <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Prostate Specific Antigen (PSA) Response</title>
          <description>PSA response is defined as a greater than or equal to a 50% decrease in PSA from the baseline without clinical or radiologic evidence of progression according to the Response Evaluation Criteria in Solid Tumors (RECIST). PSA concentration was measured at baseline on day 1/cycle 1 before treatment, then day 1 of every cycle afterwards during therapy.</description>
          <population>The analysis was based on intent-to-treat population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Greater or Equal to 80% PSA Reduction From Baseline Without Clinical or Radiologic Evidence of Progression</title>
        <description>PSA was measured at baseline on day 1/cycle 1 before treatment, then day 1 of every cycle afterwards during therapy.</description>
        <time_frame>up to 9 months</time_frame>
        <population>The analysis was based on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel +Gleevec</title>
            <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Greater or Equal to 80% PSA Reduction From Baseline Without Clinical or Radiologic Evidence of Progression</title>
          <description>PSA was measured at baseline on day 1/cycle 1 before treatment, then day 1 of every cycle afterwards during therapy.</description>
          <population>The analysis was based on intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Measurable Disease Response</title>
        <description>Measurable disease response is defined as the number of participants whose best response is complete response or partial response over the number of patients with measurable desease according to the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
        <time_frame>up to 2 years</time_frame>
        <population>Based on the participants with measurable disease</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel +Gleevec</title>
            <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Measurable Disease Response</title>
          <description>Measurable disease response is defined as the number of participants whose best response is complete response or partial response over the number of patients with measurable desease according to the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
          <population>Based on the participants with measurable disease</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression</title>
        <description>Time to PSA pregression is defined as the time at which therapy statred and ends when the PSA increased by 50% above the nadir confirmed on a second determination.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Based on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel +Gleevec</title>
            <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression</title>
          <description>Time to PSA pregression is defined as the time at which therapy statred and ends when the PSA increased by 50% above the nadir confirmed on a second determination.</description>
          <population>Based on intent-to-treat population</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="85" upper_limit="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival Time</title>
        <description>Overall survival time is the time from the start of therapy till death. Median overall survival reported here is the time when 50% of the participants are alive.</description>
        <time_frame>up to 4 years</time_frame>
        <population>Based on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel +Gleevec</title>
            <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival Time</title>
          <description>Overall survival time is the time from the start of therapy till death. Median overall survival reported here is the time when 50% of the participants are alive.</description>
          <population>Based on intent-to-treat population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" lower_limit="14.3" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>on study (up to 9 months) plus 30 days after</time_frame>
      <desc>adverse events were collected by patient reporting, investigator questioning, physical exams, lab tests, etc.</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel +Gleevec</title>
          <description>21 days per treatment cycle for up to 1 year: Day 1: Docetaxel (Taxotere) ( 70 mg/m^2 intravenously over 1 hour. Day 2: (24-36 hours later) start Gleevec (Imatinib Mesylate) 600 mg, orally, daily x 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain-other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection with normal ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>lymphatics</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>neutrophils/ granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular/ visual -other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>tearing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea (with colostomy)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea (without colostomy)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>gastrointestinal- other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>stomatitis/ pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain or cramping</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>constitutioanl symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pain -other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>rigors/ chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>neuropathy /sensory</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dermotology/ skin- other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nail changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>rash/ desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated before it reached the target accrual number due to slow accrual, leading to small number of subjects analyzed (12 out of the target number of 37).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anna Ferrari, MD</name_or_title>
      <organization>New York University Cancer Institute</organization>
      <phone>212-731-5389</phone>
      <email>anna.ferrari@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

